Valneva: 9m sales up 19%

(CercleFinance.com) - Valneva has reported 9m 2021 sales of 69.
8 million euros, up 18.7%, driven by non-product revenues, such as those related to the collaboration agreement with Pfizer for the Lyme disease vaccine.

Product sales fell slightly (-0.9% to 45.5 million euros), with the travel market still dogged by the Covid-19 pandemic. On a constant currency basis, however, sales increased by 1.8%.

For 2021, Valneva says it is now targeting total sales of between 85 and 100 million euros (compared with 80-105 million previously) and R&D expenditure of between 60 and 70 million (compared with 65-75 million previously).

Note that the share has risen by over 180% YTD.


Copyright (c) 2021 CercleFinance.com. All rights reserved.